BIOCRYST PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 536
- Market Cap
- $1.7B
- Website
- http://www.biocryst.com
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT06539507
- Locations
- 🇦🇺
Investigative site, Brisbane, Queensland, Australia
Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT06100900
- Locations
- 🇿🇦
BioCryst Investigative Site, Pretoria, South Africa
Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT05741346
- Locations
- 🇬🇧
Investigative Site, London, United Kingdom
Berotralstat Treatment in Children With Hereditary Angioedema
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 29
- Registration Number
- NCT05453968
- Locations
- 🇬🇧
Investigative Site #1, Bristol, United Kingdom
🇪🇸Investigative Site #2, Málaga, Spain
🇫🇷Investigative Site #3, Grenoble, France
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT05162066
- Locations
- 🇪🇸
Investigative Site #1, Madrid, Spain
🇪🇸Investigative Site #2, Madrid, Spain
🇬🇧Investigative Site, Oxford, United Kingdom
BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT05116787
- Locations
- 🇿🇦
Investigative Site, Pretoria, South Africa
🇰🇷InvestigativeSite, Daejeon, Korea, Republic of
BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT05116774
- Locations
- 🇬🇧
Investigative Site, London, United Kingdom
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT04933721
- Locations
- 🇿🇦
Study Center, Cape Town, South Africa
A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04702568
- Locations
- 🇬🇧
Study Center, London, United Kingdom
Oral Berotralstat Expanded Access Program
- Conditions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- BioCryst Pharmaceuticals
- Registration Number
- NCT04428632
© Copyright 2024. All Rights Reserved by MedPath